Monopar Therapeutics
ALXN1840
Wilson disease
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews ALXN1840 for Wilson disease around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 13h ago
“EL-PFDD: Attended externally led patient-focused drug development (“EL-PFDD”) meeting with the FDA on January 29, 2026.”